vs
Side-by-side financial comparison of FORRESTER RESEARCH, INC. (FORR) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
FORRESTER RESEARCH, INC. is the larger business by last-quarter revenue ($101.1M vs $57.3M, roughly 1.8× RHYTHM PHARMACEUTICALS, INC.). FORRESTER RESEARCH, INC. runs the higher net margin — -33.5% vs -83.0%, a 49.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -6.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 0.5%).
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
FORR vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $101.1M | $57.3M |
| Net Profit | $-33.9M | $-47.5M |
| Gross Margin | 56.7% | 91.6% |
| Operating Margin | -36.6% | -82.2% |
| Net Margin | -33.5% | -83.0% |
| Revenue YoY | -6.5% | 36.9% |
| Net Profit YoY | -7941.4% | -9.6% |
| EPS (diluted) | $-1.75 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $101.1M | $57.3M | ||
| Q3 25 | $94.3M | $51.3M | ||
| Q2 25 | $111.7M | $48.5M | ||
| Q1 25 | $89.9M | $32.7M | ||
| Q4 24 | $108.0M | $41.8M | ||
| Q3 24 | $102.5M | $33.3M | ||
| Q2 24 | $121.8M | $29.1M | ||
| Q1 24 | $100.1M | $26.0M |
| Q4 25 | $-33.9M | $-47.5M | ||
| Q3 25 | $-2.1M | $-52.9M | ||
| Q2 25 | $3.9M | $-46.6M | ||
| Q1 25 | $-87.3M | $-49.5M | ||
| Q4 24 | $432.0K | $-43.3M | ||
| Q3 24 | $-5.8M | $-43.6M | ||
| Q2 24 | $6.3M | $-32.3M | ||
| Q1 24 | $-6.7M | $-141.4M |
| Q4 25 | 56.7% | 91.6% | ||
| Q3 25 | 60.0% | 89.3% | ||
| Q2 25 | 55.5% | 88.6% | ||
| Q1 25 | 55.9% | 88.8% | ||
| Q4 24 | 58.8% | 90.9% | ||
| Q3 24 | 60.5% | 88.5% | ||
| Q2 24 | 57.3% | 89.9% | ||
| Q1 24 | 54.9% | 89.2% |
| Q4 25 | -36.6% | -82.2% | ||
| Q3 25 | 4.7% | -102.6% | ||
| Q2 25 | 6.2% | -93.4% | ||
| Q1 25 | -97.5% | -143.7% | ||
| Q4 24 | -0.5% | -98.6% | ||
| Q3 24 | -0.7% | -132.0% | ||
| Q2 24 | 9.3% | -139.2% | ||
| Q1 24 | -9.3% | -538.7% |
| Q4 25 | -33.5% | -83.0% | ||
| Q3 25 | -2.3% | -103.1% | ||
| Q2 25 | 3.5% | -96.1% | ||
| Q1 25 | -97.1% | -151.4% | ||
| Q4 24 | 0.4% | -103.6% | ||
| Q3 24 | -5.7% | -131.2% | ||
| Q2 24 | 5.2% | -110.9% | ||
| Q1 24 | -6.7% | -544.4% |
| Q4 25 | $-1.75 | $-0.73 | ||
| Q3 25 | $-0.11 | $-0.82 | ||
| Q2 25 | $0.20 | $-0.75 | ||
| Q1 25 | $-4.62 | $-0.81 | ||
| Q4 24 | $0.02 | $-0.71 | ||
| Q3 24 | $-0.30 | $-0.73 | ||
| Q2 24 | $0.33 | $-0.55 | ||
| Q1 24 | $-0.35 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.5M | $139.1M |
| Total Assets | $404.0M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $388.9M | ||
| Q3 25 | $65.1M | $416.1M | ||
| Q2 25 | $67.8M | $291.0M | ||
| Q1 25 | $75.6M | $314.5M | ||
| Q4 24 | $56.1M | $320.6M | ||
| Q3 24 | $62.8M | $298.4M | ||
| Q2 24 | $58.9M | $319.1M | ||
| Q1 24 | $61.4M | $201.2M |
| Q4 25 | $126.5M | $139.1M | ||
| Q3 25 | $157.7M | $148.8M | ||
| Q2 25 | $159.5M | $-11.9M | ||
| Q1 25 | $147.4M | $18.9M | ||
| Q4 24 | $229.5M | $21.7M | ||
| Q3 24 | $234.3M | $11.2M | ||
| Q2 24 | $237.1M | $39.3M | ||
| Q1 24 | $230.9M | $61.6M |
| Q4 25 | $404.0M | $480.2M | ||
| Q3 25 | $414.2M | $506.9M | ||
| Q2 25 | $436.0M | $372.7M | ||
| Q1 25 | $439.8M | $386.7M | ||
| Q4 24 | $503.9M | $392.3M | ||
| Q3 24 | $505.3M | $363.6M | ||
| Q2 24 | $524.2M | $381.8M | ||
| Q1 24 | $555.7M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.2M | $-25.4M |
| Free Cash FlowOCF − Capex | $-4.3M | — |
| FCF MarginFCF / Revenue | -4.2% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $18.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.2M | $-25.4M | ||
| Q3 25 | $1.2M | $-26.6M | ||
| Q2 25 | $-3.6M | $-23.3M | ||
| Q1 25 | $26.7M | $-40.4M | ||
| Q4 24 | $-1.8M | $-18.8M | ||
| Q3 24 | $264.0K | $-25.2M | ||
| Q2 24 | $-2.9M | $-29.1M | ||
| Q1 24 | $611.0K | $-40.7M |
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $524.0K | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $26.1M | — | ||
| Q4 24 | $-2.5M | — | ||
| Q3 24 | $-223.0K | — | ||
| Q2 24 | $-3.7M | — | ||
| Q1 24 | $-815.0K | — |
| Q4 25 | -4.2% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -3.8% | — | ||
| Q1 25 | 29.0% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -0.2% | — | ||
| Q2 24 | -3.1% | — | ||
| Q1 24 | -0.8% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.93× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
RYTM
Segment breakdown not available.
